Yin You

1.6k citations

34 papers · 1.2k indexed · h-index 17

Co-authors: Kristian Reich Michael Song Mark Lebwohl Yaung‐Kaung Shen Yves Poulin Richard G. Langley Peter Foley Wayne Langholff
Topics: Psoriasis: Treatment and Pathogenesis (31 papers)Dermatology and Skin Diseases (15 papers)Pharmaceutical studies and practices (8 papers)
Cited by: Dermatology Immunology Rheumatology
Journals: Annals of the Rheumatic Diseases Journal of the American Academy of Dermatology British Journal of Dermatology
Partner nations: United States Canada United Kingdom

In The Last Decade

Yin You

34 papers receiving 1.2k citations

Peers

Countries citing papers authored by Yin You

Since Specialization

Citations

This map shows the geographic impact of Yin You's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yin You with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yin You more than expected).

Fields of papers citing papers by Yin You

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yin You. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yin You. The network helps show where Yin You may publish in the future.

Co-authorship network of co-authors of Yin You

This figure shows the co-authorship network connecting the top 25 collaborators of Yin You. A scholar is included among the top collaborators of Yin You based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yin You. Yin You is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials 2023 ·British Journal of Dermatology ·Andrew Blauvelt,Diamant Thaçi,Kim Papp,Vincent Ho,Kamran Ghoreschi,Byung‐Soo Kim,Megan Miller,Yaung‐Kaung Shen,Yin You,Daphne Chan,(unknown),Ya‐Wen Yang,Mark Lebwohl,Alice B. Gottlieb,Jeffrey Crowley,Peter Foley	8
2	Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials 2023 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt,Mark Lebwohl,Richard G. Langley,(unknown),Ya‐Wen Yang,Daphne Chan,Megan Miller,Yin You,(unknown),(unknown),Peter Foley,Kim Papp	12
3	Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance 2022 ·Journal of the European Academy of Dermatology and Venereology ·Kristian Reich,Kenneth B. Gordon,Bruce Strober,Richard G. Langley,Megan Miller,Ya‐Wen Yang,Yaung‐Kaung Shen,Yin You,Yaowei Zhu,Peter Foley,Andrew Blauvelt	20
4	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study 2021 ·Journal of Dermatological Treatment ·Andrew Blauvelt,April W. Armstrong,Richard G. Langley,Kurt Gebauer,Diamant Thaçi,Jerry Bagel,Lyn Guenther,C. Paul,B. Randazzo,Susan Flavin,Ming-Chun Hsu,Yin You,Kristian Reich	21
5	Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis 2021 ·Journal of the American Academy of Dermatology ·Andrew Blauvelt,Tsen‐Fang Tsai,Richard G. Langley,Megan Miller,Yaung‐Kaung Shen,Yin You,Ya‐Wen Yang,Kim Papp,L. Puig	43
6	Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1 2020 ·Journal of Dermatological Treatment ·C.E.M. Griffiths,Kim Papp,Michael Song,Megan Miller,Yin You,Yaung‐Kaung Shen,Chenglong Han,Andrew Blauvelt	32
7	Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study 2020 ·American Journal of Clinical Dermatology ·Kristian Reich,April W. Armstrong,Peter Foley,Michael Song,Megan Miller,Yaung‐Kaung Shen,Yin You,Chenglong Han,Kenneth B. Gordon	27
8	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials 2020 ·RMD Open ·Philip Helliwell,Dafna D. Gladman,Soumya D. Chakravarty,Shelly Kafka,Chetan S. Karyekar,Yin You,Kim Campbell,Kristen Sweet,Arthur Kavanaugh,Lianne S. Gensler	39
9	15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials 2020 ·Journal of the American Academy of Dermatology ·Kristian Reich,Bruce Strober,Richard G. Langley,Michael Song,Yaung‐Kaung Shen,Yin You,Peter Foley,Andrew Blauvelt	2
10	Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials 2019 ·The Journal of Rheumatology ·Iain B. McInnes,L. Puig,Alice B. Gottlieb,Christopher T. Ritchlin,Michael Song,Yin You,Shelly Kafka,G. James Morgan,Proton Rahman,Arthur Kavanaugh	9
11	Efficacy of ustekinumab in biologic-naïve patients with psoriatic arthritis by prior treatment exposure and disease duration: data from PSUMMIT 1 and PSUMMIT 2 2019 ·RMD Open ·Iain B. McInnes,Soumya D. Chakravarty,(unknown),Shelly Kafka,Elizabeth C. Hsia,Yin You,Arthur Kavanaugh	17
12	Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies 2019 ·Kenneth B. Gordon,Chenglong Han,Shu Li,Yin You,Michael Song,Steven Fakharzadeh,Jeffrey Crowley,Kristian Reich	4
13	Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study 2018 ·Journal of the European Academy of Dermatology and Venereology ·Kenneth B. Gordon,April W. Armstrong,Chenglong Han,Peter Foley,Michael Song,Yasmine Wasfi,Yin You,Yaung‐Kaung Shen,Kristian Reich	60
14	Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies 2018 ·American Journal of Clinical Dermatology ·April W. Armstrong,Kristian Reich,Peter Foley,Chenglong Han,Michael Song,Yaung‐Kaung Shen,Yin You,Kim Papp	34
15	Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]) 2016 ·Journal of the American Academy of Dermatology ·Bruce Strober,Robert Bissonnette,David Fiorentino,Alexa B. Kimball,Luigi Naldi,Neil H. Shear,Kavitha Goyal,Steven Fakharzadeh,Stephen Calabro,Wayne Langholff,Yin You,Claudia Martins Galindo,Seina Lee,Mark Lebwohl	63
16	Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2) 2016 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh,L. Puig,Alice B. Gottlieb,Christopher T. Ritchlin,Yin You,Shu Li,Michael Song,B. Randazzo,Proton Rahman,Iain B. McInnes	126
17	SAT0563 Long Term Improvements in Physical Function are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients 2015 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh,L. Puig,Alice B. Gottlieb,Christopher T. Ritchlin,S. Li,Yin You,Alan M. Mendelsohn,Michael Song,Proton Rahman,Iain B. McInnes	2
18	OP0174 Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study 2015 ·Annals of the Rheumatic Diseases ·Arthur Kavanaugh,L. Puig,Alice B. Gottlieb,Christopher T. Ritchlin,Yin You,(unknown),Alan M. Mendelsohn,Michael Song,Proton Rahman,Iain B. McInnes	3
19	Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis 2015 ·JAMA Dermatology ·Robert E. Kalb,David Fiorentino,Mark Lebwohl,John Toole,Yves Poulin,Arnon D. Cohen,Kavitha Goyal,Steven Fakharzadeh,Stephen Calabro,Marc Chévrier,Wayne Langholff,Yin You,Craig L. Leonardi	266
20	Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis 2011 ·Journal of the American Academy of Dermatology ·Alexa B. Kimball,Philippe Szapary,Ulrich Mrowietz,Kristian Reich,Richard G. Langley,Yin You,Ming-Chun Hsu,Newman Yeilding,Daniel J. Rader,Nehal N. Mehta	103

About Yin You

Yin You is a scholar working on Dermatology, Immunology and Rheumatology, having authored 34 papers that have together received 1.2k indexed citations. Recurring topics across this work include Psoriasis: Treatment and Pathogenesis (31 papers), Dermatology and Skin Diseases (15 papers) and Pharmaceutical studies and practices (8 papers). The work is most often cited by research in Dermatology (478 citations), Immunology (1.0k citations) and Rheumatology (341 citations). Yin You has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Kristian Reich, Michael Song, Mark Lebwohl, Yaung‐Kaung Shen, Yves Poulin, Richard G. Langley, Peter Foley, Wayne Langholff, Kavitha Goyal and Steven Fakharzadeh. Their work appears in journals such as Annals of the Rheumatic Diseases, Journal of the American Academy of Dermatology and British Journal of Dermatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact